AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

AbbVie (NYSE: ABBV) Q4 2024 Earnings Call Jan 31, 2025, 9:00 a.m. ET Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

Shares of AbbVie ( ABBV 6.95%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

Reports Q4 revenue $15.1B, consensus $14.83B. “2024 was a year of significant progress for AbbVie (ABBV). Our growth platform delivered ...

AbbVie Inc . (NYSE:ABBV) delivered strong financial results for Q4 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.16, compared to the forecast of $2.06. The company ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.

Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

AbbVie (NYSE: ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the ...